TuHURA Biosciences (HURA) Expected to Announce Earnings on Friday

TuHURA Biosciences (NASDAQ:HURA) is expected to be issuing its resultson Friday, May 15th. Analysts expect the company to announce earnings of ($0.12) per share for the quarter.

TuHURA Biosciences (NASDAQ:HURA) last posted its quarterly earnings results on Tuesday, March 31st. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). On average, analysts expect TuHURA Biosciences to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

TuHURA Biosciences Trading Up 0.8%

HURA stock opened at $2.42 on Wednesday. The stock has a 50-day moving average price of $2.09 and a two-hundred day moving average price of $1.60. TuHURA Biosciences has a 12-month low of $0.41 and a 12-month high of $4.20. The company has a market cap of $154.11 million, a PE ratio of -3.84 and a beta of -0.01.

Wall Street Analysts Forecast Growth

HURA has been the subject of a number of research reports. Citigroup started coverage on TuHURA Biosciences in a research report on Monday, April 27th. They set an “outperform” rating for the company. Rodman & Renshaw started coverage on TuHURA Biosciences in a research note on Wednesday, April 15th. They set a “buy” rating on the stock. Citizens Jmp started coverage on TuHURA Biosciences in a research note on Monday, April 27th. They set a “market outperform” rating and a $9.00 price objective on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of TuHURA Biosciences in a research note on Tuesday, April 21st. Finally, Wall Street Zen cut TuHURA Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $9.00.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Vanguard Group Inc. increased its holdings in TuHURA Biosciences by 1.6% in the third quarter. Vanguard Group Inc. now owns 2,269,666 shares of the company’s stock valued at $5,629,000 after buying an additional 35,426 shares during the last quarter. Geode Capital Management LLC increased its holdings in TuHURA Biosciences by 6.4% in the fourth quarter. Geode Capital Management LLC now owns 662,481 shares of the company’s stock valued at $501,000 after buying an additional 39,710 shares during the last quarter. State Street Corp increased its holdings in TuHURA Biosciences by 4.9% in the fourth quarter. State Street Corp now owns 289,133 shares of the company’s stock valued at $219,000 after buying an additional 13,594 shares during the last quarter. Deutsche Bank AG increased its holdings in TuHURA Biosciences by 209.8% in the fourth quarter. Deutsche Bank AG now owns 79,816 shares of the company’s stock valued at $61,000 after buying an additional 54,051 shares during the last quarter. Finally, Barclays PLC increased its holdings in TuHURA Biosciences by 42.6% in the fourth quarter. Barclays PLC now owns 52,615 shares of the company’s stock valued at $40,000 after buying an additional 15,725 shares during the last quarter. Institutional investors and hedge funds own 0.62% of the company’s stock.

TuHURA Biosciences Company Profile

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.